SCHEMBL7454625

SCHEMBL7454625

O=C1CSc2ccc(Cl)cc2N1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.59
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
MAOA P21397 3/20 0.53
MAOB P27338 3/20 0.53
EPHX2 P34913 1/20 0.53
AHR P35869 2/20 0.51
CMA1 P23946 1/20 0.51
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 4/20 0.47
RECQL P46063 2/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
CASP1 P29466 1/20 0.47
CYP2C19 P33261 1/20 0.47
SLC8B1 Q6J4K2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4219649 0.87 MAOB (0.64) HTTMAOAMAOBEPHX2AHR
SCHEMBL8853550 0.83 HDAC1 (0.57) LMNAAHRCMA1MAPTTP53
SCHEMBL9629681 0.80 KMT2A (0.49) HTTLMNAAHRCMA1MAPT
SCHEMBL10511911 0.79 MAOA (0.53) HTTALDH1A1LMNAMAOAMAOB
SCHEMBL30199790 0.79 HTT (0.59) HTTALDH1A1LMNAMAOAMAOB
SCHEMBL3601956 0.79 HTT (0.59) HTTALDH1A1LMNAMAOAMAOB
SCHEMBL15875502 0.79 HTT (0.59) HTTALDH1A1LMNAMAOAMAOB
SCHEMBL10509516 0.79 HTT (0.59) HTTALDH1A1LMNAMAOAMAOB
SCHEMBL1332876 0.79 HTT (0.59) HTTALDH1A1LMNAMAOAMAOB
SCHEMBL19630003 0.79 HTT (0.59) HTTALDH1A1LMNAMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242945-B2 Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof Temple University—Of the Commonwealth System of Higher Education (US) 2016-01-26 US disclosed
US-20140086941-A1 SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2014-03-27 US disclosed
WO-2011151361-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-12-08 WO disclosed
WO-2011151361-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-12-08 WO disclosed
US-5141935-A Dihydrobenz thiazine derivative and microorganism control agent UBE INDUSTRIES, LTD. (JP) 1992-08-25 US disclosed
EP-0162776-B1 HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS USEFUL AS ALDOSE REDUCTASE INHIBITORS CONTAINING THEM LABORATOIRES UPSA (FR) 1989-04-19 EP disclosed
US-4755509-A Heterocyclic aldose reductase inhibitors and methods of using them Carbipem (FR) 1988-07-05 US disclosed
EP-0162776-A2 Heterocyclic derivatives, process for their preparation and medicaments useful as aldose reductase inhibitors containing them LABORATOIRES UPSA (FR) 1985-11-27 EP disclosed
US-4223136-A 2,3-Dihydro-3-oxo-5H-pyrido[3,4-b][1,4]-benzothiazine-4-carbonitriles G. D. SEARLE & CO. (US) 1980-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140086941-A1 SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF RB1, AR, CDK4 HTT 672/4885ALDH1A1 37/4885LMNA 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.